iX Biopharma

SINGAPORE (Nov 1): Here are some factors and stocks that could move the market this Tuesday morning:

SINGAPORE (Oct 31): iX Biopharma announced that it has secured a Canadian patent for its WaferiX drug delivery technology.

SINGAPORE (Oct 13): DBS Group Research has derived a fair value estimate of 43 cents for iX Biopharma in its preliminary assessment of what it deems a high-risk stock, with a view that investors should expect 0-20% potential returns from the stock over th

SINGAPORE (Sept 16): News that iX Biopharma’s drug to treat male erectile dysfunction is close to appearing on pharmacy shelves has got the market excited.

SINGAPORE (Sept 14): Here are some stocks that could move the market this Wednesday morning:

SINGAPORE (Sept 13): Specialty pharmaceutical company iX Biopharma on Tuesday announced positive results in a pivotal bioequivalence study of its male erectile dysfunction drug.

SINGAPORE (Aug 26): Singapore stocks ended weaker on Friday, retreating from its highest level in around four weeks as Asian indexes get stuck in limbo pending policy guidance from US Federal Reserve Chairwoman Janet Yellen.

SINGAPORE (Aug 26): iX Biopharma is a small Catalist-listed Singapore company focusing on a big goal: Developing pain management drugs that are an alternative to opioids, and the optimum system to deliver these drugs into the body.

SINGAPORE (Aug 25): iX Biopharma reported net losses of $7.7 million for FY16, a 25% improvement over the net losses of $10.4 million in FY15.